SAN FRANCISCO, October 30, 2025 — Leads & Copy — iRhythm Technologies, Inc. (NASDAQ: IRTC) reported its financial results for the third quarter of 2025, with revenue reaching $192.9 million, a 30.7% increase compared to the same period in 2024. Gross margin improved to 71.1%, and the company’s unrestricted cash, cash equivalents, and marketable securities totaled $565.2 million as of September 30, 2025. The company has increased its fiscal year 2025 guidance for revenue and adjusted EBITDA margin.
Key operational highlights include record quarterly revenue driven by the long-term continuous monitoring business, sustained demand for Zio AT, and progress in value-based care accounts and international markets. Recent publications of AVALON1 real-world evidence and AMALFI3 randomized clinical trial continue to support Zio’s clinical value proposition and proactive arrhythmia monitoring strategies.
iRhythm’s President and CEO, Quentin Blackford, noted the scalability of their platform and the growing adoption of their technology, highlighting the company’s expansion into primary care and population health programs, EHR integration, and new clinical evidence. The company also anticipates being free cash flow positive on an annual basis for the first time in its history.
iRhythm projects revenue for the full year 2025 between $735 million to $740 million. Adjusted EBITDA margin for the full year 2025 is expected to range from approximately 8.25% to 8.75% of revenues.
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
Investor Contact:
Stephanie Zhadkevich
investors@irhythmtech.com
Media Contact:
Kassandra Perry
irhythm@highwirepr.com
Source: iRhythm Technologies, Inc.
